Risk Factors Affecting Outcome of Second HLA-Matched Sibling Donor Transplantations for Graft Failure in Severe Acquired Aplastic Anemia

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 5, 2009, Pages 626-631

  Horan, John T ^a   Carreras, Jeanette ^b   Tarima, Sergey ^b   Camitta, Bruce M ^b   Gale, Robert Peter ^c   Hale, Gregory A ^d   Hinterberger, Wolfgang ^e   Marsh, Judith ^f   Passweg, Jakob R ^g   Walters, Mark C ^h   Eapen, Mary ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c CELGENE CORPORATION   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Graft failure; Second transplantation; Severe aplastic anemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; ENGRAFTMENT; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SIBLING; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; GRAFT REJECTION; HEMATOPOIESIS; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; PROGNOSIS; REOPERATION; RISK FACTORS; SIBLINGS; TISSUE DONORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63749128979     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.01.023     Document Type: Article

References (18)

1. Doney K., Leisenring W., Storb R., et al. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med 126 (1997) 107-115
2. Bacigalupo A., Brand R., Oneto R., et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy: the European Group for Blood and Marrow Transplantation experience. Semin Hematol 37 (2000) 69-80
3. Fuhrer M., Rampf U., Baumann I., et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 106 (2005) 2102-2104
4. Locasciulli A., Oneto R., Bacigalupo A., et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 92 (2007) 11-18
5. Passweg J.R., Socie G., Hinterberger W., et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved?. Blood 90 (1997) 858-864
6. Champlin R.E., Horowitz M.M., van Bekkum D.W., et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 73 (1989) 606-613
7. Champlin R.E., Perez W.S., Passweg J.R., et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 109 (2007) 4582-4585
8. McCann S.R., Bacigalupo A., Gluckman E., et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 13 (1994) 233-237
9. Stucki A., Leisenring W., Sandmaier B.M., et al. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood 92 (1998) 2742-2749
10. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825-828
11. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
12. Klein J., and Moeschberger M. Survival Analysis: Techniques of Censored and Truncated Data (2003), Springer-Verlag, New York
13. Klein J.P., and Andersen P.K. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics 61 (2005) 223-229
14. Andersen P.K., Klein J.P., and Zhang M.J. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med 18 (1999) 1489-1500
15. de Medeiros C.R., Bitencourt M.A., Medeiros B.C., et al. Second bone marrow transplantation for severe aplastic anemia: analysis of 34 cases. Bone Marrow Transplant 28 (2001) 941-944
16. Schrezenmeier H., Passweg J.R., Marsh J.C., et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 110 (2007) 1397-1400
17. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 110 (2007) 3784-3792
18. Fraser C.J., Bhatia S., Ness K., et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 108 (2006) 2867-2873